We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Vanda Pharmaceuticals Inc | NASDAQ:VNDA | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.0399 | 0.89% | 4.5199 | 4.00 | 6.29 | 4.625 | 4.45 | 4.57 | 821,939 | 05:00:08 |
From Oct 2023 to Apr 2024
By Dean Seal
A federal court has denied the government's bid to throw out a lawsuit from Vanda Pharmaceuticals accusing the Food and Drug Administration of handing trade secrets to generic drug makers.
Vanda said on Friday that the U.S. Court of Federal Claims permitted some of its claims against the government to proceed following oral arguments on a motion to dismiss last week.
The biopharmaceutical company said in its lawsuit filed in May that the FDA improperly provided confidential details about its sleep-wake disorder drug Hertlioz and its schizophrenia treatment Fanapt to generic drug manufacturers while it reviewed Vanda's new drug applications.
Vanda is seeking compensation and will now engage in discovery to support its claims, the company said Friday.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
January 19, 2024 16:42 ET (21:42 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Vanda Pharmaceuticals Chart |
1 Month Vanda Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
